Slide 1: Australian Equities Day
For personal use only Australian Equities Day 3 October 2025
Slide 2: Agenda
• What is TruScreen • The Global Market • TruScreen’s Top Line For personal use only • Public Screening Programs • FY 2026 Growth Strategy • Revenue Outlook • Appendix
Slide 3: What is TruScreen?
For personal use only What is TruScreen?
Slide 4: What is TruScreen?
TruScreen Group Ltd is a revenue generating Life Science company with a unique, AI-enabled real-time cervical cancer screening device. For personal use only The Company manufactures two devices : • one made in China for use in China, where locally manufactured products have preferential market acces
Slide 5: How The TruScreen Device works
How The TruScreen Device works Handheld device (HHD) For personal use only Single Use Sensor (SUS) Intelligent Cradle 5
Slide 6: The Global Cervical Cancer Screening Market
For personal use only The Global Cervical Cancer Screening Market
Slide 7: Cervical Cancer Is A Global Public Health Issue
Cervical Cancer Is A Global Public Health Issue† Fourth most common cancer in For personal use only Every 2 minutes, a Most diagnoses women worldwide, but preventable - in occur at working age women dies from fact only one of a handful of cancers cervical cancer. (35-44) that we understand fully. Ar
Slide 8: WHO & Countries are committed to eliminating Cervical Cancer
WHO & 194 Countries are committed to eliminating Cervical Cancer • In 2020 The World Health Organisation (WHO) and 194 member countries agreed on a strategy to eliminate cervical cancer this century For personal use only 90% 70% 90% HPV Vaccination Screening coverage & Management of coverage for gir
Slide 9: TruScreen is WHO-recognised and positioned for growth
TruScreen is WHO-recognised and positioned for growth For personal use only • TruScreen, as a stand-alone primary screening device has regulatory approvals and distribution in 3 of the worlds 4 most populous countries (India, China and Indonesia) and 2 of the world’s 4 largest economies (China and I
Slide 10: The Size of the Cervical Cancer Screening Market
The Size of the Cervical Cancer Screening Market 2024 The global cervical cancer screening market is valued at ~USD 7.9 billion in 2024 $7.9bn For personal use only It is projected to reach USD 14.5 billion by 2033, an annual growth rate of 5.8% (CAGR).1 TruScreen currently makes up just 0.02% of th
Slide 11: Key Drivers for Global Growth in Cervical Cancer Screening
Key Drivers for Global Growth in TruScreen Positioned to Capitalise on Cervical Cancer Screening1 these Drivers For personal use only Expansion of organized government TruScreen selected for Public Screening programs screening programs in emerging economies in Zimbabwe, Vietnam, Uzbekistan and Eswat
Slide 12: TruScreen's Top Line
For personal use only Top Line TruScreen’s
Slide 13: The Top Line
The Top Line 1m+ 232 1000+ For personal use only Women Devices operational Healthcare professionals WHO and UNITAID Screened worldwide trained recognition 112 14 9 30+ Hospitals / Clinics Countries with Regulatory Clinical Performance using TruScreen regulatory approval approvals in process validati
Slide 14: The Top Line
The Top Line $ $ FY25 sales were NZ$ 1.7m, FY26 sales are forecast exceed NZ$ 2.8m, comprised primarily from sales to making the Company monthly cash flow China positive in March 2026 For personal use only This result will be boosted in FY26 by major public FY26 revenue is forecast to be made up of
Slide 15: The Top Line: Global Recognition
The Top Line Global Recognition Registration and Sales activity in Russia, Kazakhstan, Kyrgyzstan, Armenia and Belarus Uzbekistan product registration completed to enable the validation Inclusion in Chinese Obstetricians trial of TruScreen for a national cervical cancer screening program and Gynecol
Slide 16: TruScreen Regulatory Approvals
The Top Line TruScreen Regulatory Approvals International Quality Recognized by International Approvals: Accreditation: • World Health Organisation (WHO) • CE Mark, European Union • ISO 13485 For personal use only • UNITAID • NMPA, China • IEC 60601-1 • Clinton Health Access Initiative • TGA, Austra
Slide 17: FY25 Medical Affairs achievements
The Top Line FY25 Medical Affairs achievements OCT 24 • Included in UNITAID’s technology landscape report “Screening and treatment of pre-cancerous lesions for secondary prevention of cervical cancer”, the only opto-electrical device included. • Selected by StartUs Insights as one of six global comp
Slide 18: DaltonBio Strategic Alliance
The Top Line DaltonBio Strategic Alliance • Q4 FY25 - Memorandum of Understanding signed with Hangzhou Dalton Bioscience (DaltonBio) • Q1 FY26 - TruScreen and Dalton Bio sign Distribution Agreement for For personal use only HPV products in India 1. TruScreen to be appointed a global distributor of D
Slide 19: HPV tests-DHTM series by DaltonBio
The Top Line HPV tests-DHTM series by DaltonBio Human Papillomavirus (HPV) Nucleic Acid Detection Systems HPV Self Sampling Collection System For personal use only The DH3 kit is used to detect 14 high-risk HPV types that cause cervical cancer, provides relative viral load values, and it has clinica
Slide 20: Public Screening Programs
For personal use only Public Screening Programs
Slide 21: Entry into Public Screening Programs
Entry into Public • TruScreen’s sales to date have been achieved largely through traditional sales Screening Programs of devices and Single Use Sensors to hospitals and clinics. In FY25 these For personal use only traditional channels made up 99% of sales. • In FY26, public screening programs are ex
Slide 22: Vietnam
Vietnam For personal use only A 5-year program to screen 260,000 women for cervical cancer using TruScreen in Ho Chi Minh City launched in July 2025. The program is a partnership between TruScreen, Ho Chi Minh City Public Health Association and distributor Gorton Health April 12 2025. TruScreen Chai
Slide 23: Zimbabwe
Zimbabwe For personal use only Since 2022, TruScreen has screened 14,000 women in the Masvingo Province, Zimbabwe, through a public screening program managed by the Zimbabwe National AIDS Council (NAC) and the Ministry of Health and Childcare. Re-validation will be completed in September 2025 to rec
Slide 24: Uzbekistan
Uzbekistan For personal use only TruScreen CEO Marty Dillon signs MOU with Senator & Professor Aral Ataniyazova in Tashkent, Uzbekistan Following TruScreen’s receipt of regulatory approval by the National Pharmaceutical Safety Committee in Uzbekistan in June 2025, a 500 patient pilot project is plan
Slide 25: FY 2026 Strategy
For personal use only FY 2026 Strategy
Slide 26: FY 2026 Strategy: Commercial Strategy
FY 2026 Strategy Commercial Strategy DIRECT INDIRECT THE INDIRECT CHANNEL CHANNEL CHANNEL • Global distributors For personal use only THE DIRECT CHANNEL • Major public screening programs supported by national Ministries of Health and Non-Government Organisations – Vietnam, Uzbekistan and Zimbabwe pl
Slide 27: Key Objectives for FY2026
FY 2026 Strategy Key Objectives for FY2026 Development Monthly PSP Dalton of Development cash flow For personal use only Indonesian of Indian success sales and ASEAN market positive market in Mar 26 • Successful execution of PSPs • Build on initial India • Build Indonesia sales • Build sales with in
Slide 28: Key Enablers of Success
FY 2026 Strategy Key Enablers of Success Build Strengthen Continued evidence New BDM Marcomms operational For personal use only distributor base and hire relationships international focus cost- effectiveness recognition HIRED AUGUST 2025 • Dalton relationship nurture, • Refine partner support • Get
Slide 29: Revenue Outlook
For personal use only Revenue Outlook
Slide 30: Revenue Outlook
Revenue Outlook FY25 Sales (Actual) FY26 Sales (Forecast) NZ$ 1.71m NZ$ 2.8m (+64% YOY increase with increased diversification of revenue) For personal use only 30
Slide 31: TruScreen Expected Sales Increase FY26
Revenue Outlook TruScreen Expected Sales Increase FY26 NZ$ 2.8m Public Screening Expected sales Six key Program to Public Screening > NZ$ 100k provinces resume; to commence; For personal use only Ho Chi Minh City targeted; Expected sales Expected sales Public Screening Expected sales > NZ$ 250k Dalt
Slide 32: Revenue Outlook: China, Vietnam, India
Revenue Outlook China • FY26 expectations are a 13% uptick on FY25 sales • Distributor SWXT have forecast sales of 40 Devices and 150,000 SUS for FY 26 >NZ$1.75m • Expected to represent ~60% of Global Sales – a ~30% reduction in our reliance on China sales (87% in FY25), mitigating a key business ri
Slide 33: Revenue Outlook: Indonesia, Uzbekistan, Mexico
Revenue Outlook Indonesia FY26 forecast is based upon the contracted Year 1 of sales to new distributor PT Mawar Mitra Medika, with first order already placed. >NZ$100k FY26 sales expectations underpinned by the commencement of 500- For personal use only Uzbekistan patient pilot program in Karakalpa
Slide 34: Revenue Outlook: Zimbabwe, Southeast Asia, Dalton Bio
Revenue Outlook Zimbabwe FY26 forecast is based upon the recommencement of public screening programs in metropolitan and regional Zimbabwe, once Ministry of Health >NZ$250k Re-Validation has been finalised in September 2025. For personal use only Singapore, TruScreen is working with distributor INTE
Slide 35: Thank you
Thank you. For personal use only Martin Dillon Guy Robertson CEO Chief Financial Officer M - +61 449 115 065 M – +61 407 983 270 E – martindillon@truscreen.com E – guyrobertson@truscreen.com TruScreen Suite 3.03 18 Orion Rd Lane Cove West NSW 2066 Australia www.truscreen.com
Slide 36: Appendix
For personal use only Appendix
Slide 37: The TruScreen Technology
For personal use only The TruScreen Technology
Slide 38: How it works
How it works 1 a pen-like wand covered by a Single Use Sensor (SUS) is used For personal use only to gently touch multiple spots on the cervix. The SUS contains a precision lens and electrodes which interfaces with the cervix. It sends and picks up low level electrical and optical signals (14 readin
Slide 39: How it works
How it works 2 The TruScreen Handheld Device (HHD) then applies an integrated AI-enabled algorithm to analyse these For personal use only signals and compares them to an integrated database of 2,000 patients drawn from a wide range of geographic and ethnic backgrounds with differing histological dia
Slide 40: For personal use only
Clinicians/physicians are able to immediately plan appropriate patient care Device has an expected life span of 5–7 years Disposable SUS is used once per test per patient - ensures there is no chance of cross-infection For personal use only between patients The entire patient data collection
Slide 41: Why TruScreen?
Why TruScreen? Truscreen Liquid Based Cytology (LBC) HPV DNA Real time results For personal use only Low infrastructure costs Strong clinical results Objective results Low training threshold Portable No cell or tissue samples taken 41
Slide 42: COGA Trial
COGA Trial (n= 15,661, 2018-2021) • TruScreen specificity surpassed Liquid Based Cytology (LBC) and hrHPV • TruScreen determined to be a simple, effective and rapid real-time cervical cancer screening method • TruScreen determined to be an appropriate primary cervical cancer screening tool in region
Slide 43: The TruScreen Journey
The TruScreen Journey Building the Fundamentals 2014 - 2020 Building for the Future 2020-2024 2025 & Beyond 2022 • China Growth continues For personal use only • Managing COVID-19 challenges • Distribution of Dalton Bio IVD HPV DNA • Cost reduction products 2017 Dec 2019 May • Manufacturing and busi
Slide 44: The TruScreen Team
For personal use only The TruScreen Team
Slide 45: The Board
The Board For personal use only Mr. Anthony Ho Mr. Christopher Horn Dr. Dexter Cheung Christine Pears B. Com (UNSW), CA, FAICD, FCIS, FGIA B. Com (UNSW), FCA B. Tech (Hons), M.Eng, PHD B. Com (Auck), CA, MinstD (NZ) Non-executive Chairman Non-executive Independent Director Non-executive Director Non
Slide 46: The Executive Team
The Executive Team For personal use only Dr Jerry Tan Martin Dillon Guy Robertson, B. Com (Hons.) CA B. Med (Clinical), M.Com, CPA CEO CFO & Company Secretary General Manager Commercial Martin Dillon skilfully managed the company’s Guy is an experienced finance executive, having held Dr. Tan has ext
Slide 47: The Executive Team
The Executive Team For personal use only Dr Carolina Velasquez Usharani Raji MBBS, M ClinRes B Eng (Hons), MSc Medical Affairs and Training Manager Production Manager Dr Carolina Velasquez gained her Bachelor of Usha is an experienced engineer with a strong background in Medicine and Surgery at Pont
Slide 48: Key market activities
For personal use only Key market activities
Slide 49: Growth Strategies
Growth Strategies Market expansion to continue with Strengthen vertical Asian market from China the key focus Indonesia through China, and capitalise on Indian distribution network For personal use only Focus on key growth provinces (Shandong, Target Govt and NGO funded Jiangsu,, Hunan, Zhejiang, Gu
Slide 50: Growth Strategies (cont.)
Growth Strategies (cont.) Focus on countries with limited or nil Expand product portfolio to include Dalton cervical screening capability Bio HPV related IVD products DNA tests, including HPV DNA tests and self sampling For personal use only Developing strategic partnerships for Reduce SUS and Devic
Slide 51: FY2026 active markets - at a glance
FY2026 active markets - at a glance (PSP = Public Screening Program) China: TRU sales (through SWXT and Dalton For personal use only Uzbekistan distribution network) PSP Mexico India: TRU sales Vietnam TRU sales PSP Dalton sales Singapore, Malaysia, Thailand, TRU sales Indonesia Zimbabwe PSP TRU sal
Slide 52: Key market: China
Key market China accounted for over 85% of global sales and exceeded budget in FY25 and is now poised for expansion in 6 key provinces • Key provinces for growth: TruScreen’s China distributor Beijing Siweixiangtai CHINA Technology Co Ltd (SWXT) is targeting 6 key provinces for growth in FY26 - For
Slide 53: China: private sector and insurance
• Private Sector Expansion: SWXT targeting of the growing China private health sector including private clinic and Health Check Centre approvals in Jiangsu and Shenzhen, and entry into the Luxury Hospital and Traditional Chinese Medicine Hospital sectors. • Public Health Insurance: In addition to ha
Slide 54: Vietnam: 260,000 women program in Ho Chi Minh City
TruScreen selected to screen 260,000 women in Ho Chi Minh City and adoption in Vietnam picks up pace – expected to be second largest market in FY2026 5-year program to screen 260,000 women for cervical cancer in Ho Chi Minh City launched July 2025 Following the signing of a Memorandum of Understandi
Slide 55: TruScreen re-enters India
TruScreen re-enters India with appointment of Renovate Biologicals Pvt Ltd in April 2025 INDIA India holds one-sixth of the world's population and one woman dies from cervical cancer every eight minutes in the country. The cervical cancer screening rate is only 2%, and India’s 468 million National A
Slide 56: Indonesia product registration and distributor
Indonesia product registration completed and distributor appointed, with commercial activity commenced in May 2025 INDONESIA 96 million • Distributor Appointed: Following the completion of product registration, women of screening age* For personal use only TruScreen appointed a new Indonesian medica
Slide 57: Mexico second largest market in FY2025
Mexico second largest market in FY2025, accounting for 7% of sales – with major private health insurer opportunity in play MEXICO Mexico has approximately 46 million women of screening age*, and cervical 46 million women of cancer is the second most prevalent cancer amongst women. screening age* HPV
Slide 58: African opportunities progress
African opportunities progress, with Zimbabwe PSP expected to launch Q3 FY2026 Zimbabwe ZIMBABWE Since 2022, TruScreen has screened 14,000 women in the Masvingo Province, Zimbabwe, through a public screening program managed by the Zimbabwe National AIDS Council (NAC) 5 million For personal use only
Slide 59: References
References *Women aged 15-64 years as detailed in the World Fact Book : https://www.cia.gov/the-world- factbook/ 1 Xiao, F., Sui, L. Evaluation of a real-time optoelectronic method for the detection of cervical intraepithelial neoplasia and cervical cancer in patients with different transformation z
Slide 60: Disclaimers
Disclaimers This presentation has been prepared by TruScreen Group Limited (the “Company”) and is dated 25 August 2023. This presentation contains summary information about the Company and its activities which is current as at the date of this presentation. The information in this presentation is of